drugset
drugset / Trial / NCT02797847

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

NCT02797847 ↗

Phase 1 Completed 80 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC02 in healthy subjects.

Timeline

Start
2016-06-07
Primary completion
2018-01-12
Completion
2018-01-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vutrisiran Small interfering RNA (siRNA) — Subcutaneous

Indications

No indication recorded.